The new drug, LX2006, has already received the FDA's fast track designation. This latest distinction was based on early data from two separate clinical trials.
The new document, published in both the Journal of the American College of Cardiology and Circulation, highlights the significant progress researchers and clinicians have made in this area in recent years.
The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.
One of the most formidable societies of medical professionals in the U.S. is going toe-to-toe with Robert F. Kennedy’s HHS over changing vaccination recommendations.
Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.